Johnson & Johnson s clinical trial for COVID-19 vaccine at Colina area, Santiago
SANTIAGO (Reuters) – Earlier this month, Johnson & Johnson abruptly called for an end to enrollment in its coronavirus vaccine trial and told scientists from six Latin American countries to wrap up their work within 48 hours, two researchers told Reuters.
The halt was due to J&J’s decision, announced later on that same day on Dec. 9, to cap the number of participants at about 40,000 people globally, down from a previous plan for 60,000.
The drugmaker said that a surge in coronavirus cases in the areas it was testing would give it enough data to vet the vaccine.
INSIGHT- Inside J&J s Latam COVID vaccine trial, a rush to recruit is followed by disappointment
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Tras apuro por reclutar voluntarios, ensayos de la vacuna J&J causan decepción en América Latina
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Tras apuro por reclutar voluntarios, ensayos de la vacuna J&J causan decepción en América Latina
reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.